Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE

Bank of America Corp DE boosted its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 55.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 272,233 shares of the company's stock after purchasing an additional 96,864 shares during the period. Bank of America Corp DE owned about 0.25% of Tango Therapeutics worth $841,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Tango Therapeutics during the 4th quarter valued at $33,000. Ameriprise Financial Inc. acquired a new stake in Tango Therapeutics during the fourth quarter valued at $35,000. Teacher Retirement System of Texas grew its stake in Tango Therapeutics by 35.8% in the fourth quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company's stock valued at $45,000 after purchasing an additional 3,831 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new position in Tango Therapeutics in the 4th quarter worth about $45,000. Finally, Price T Rowe Associates Inc. MD increased its position in Tango Therapeutics by 29.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,998 shares of the company's stock worth $65,000 after purchasing an additional 4,813 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Price Performance

NASDAQ TNGX opened at $4.26 on Monday. Tango Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $12.02. The stock's 50-day moving average is $1.69 and its two-hundred day moving average is $2.36. The firm has a market cap of $461.76 million, a P/E ratio of -3.61 and a beta of 1.24.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.02). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. On average, equities analysts expect that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a research note on Monday, April 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tango Therapeutics has a consensus rating of "Buy" and an average price target of $12.20.

Tango Therapeutics Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.